• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

UK Boosts Cell and Gene Therapy with New Manufacturing Center

Article

UK Business Secretary Greg Clark and Science Minister Sam Gyimah today opened the Cell and Gene Therapy Catapult’s (CGT Catapult) unique cell and gene therapy manufacturing center in Stevenage, UK.   Backed by over £60 million ($84m) of UK Government investment from its Industrial Strategy, the center will support and develop the rapidly growing global cell and gene therapy industry in the UK while demonstrating the government’s modern Industrial Strategy in action.   The center will also supply the network of world-first, UK-based Advanced Therapies Treatment Centres (ATTCs) formed as part of the government’s investment of £146 million ($204m) through its Industrial Strategy Challenge Fund in medicines manufacturing.    Greg Clark commented: “We are determined to make the UK the most innovative nation in the world through our Industrial Strategy and its Grand Challenges, which is why we are investing a record £7 billion ($9.8 bn) in R&D by 2021, the highest increase in 40 years, and have committed to investing 2.4% of GDP on R&D by 2027.”   For more information, visit ct.catapult.org.uk or http://www.gov.uk/innovate-uk.

Recent Videos
Related Content